Replies to post #106172 on Biotech Values

[DewDiligence]

ABT withdraws BLA/MAA for briakinumab (ABT-874):

http://sec.gov/Archives/edgar/data/1800/000110465911001492/a11-1977_28k.htm

Evidently, the FDA and EMA think more studies are needed to support approval of this compound in psoriasis.